Drug Trial Radar · NCT05205200
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
338
Planned (sponsor's estimate)
Start
Jun 6, 2022
Primary completion
Feb 1, 2025
Study completion Aug 1, 2026
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University Cancer Hospital & Institute; First Hospital of China Medical University; Sun Yat-sen University; First Affiliated Hospital Xi'an Jiaotong University; Liaoning Cancer Hospital & Institute; Chongqing University Cancer Hospital; Northern Jiangsu People's Hospital; Fujian Medical University Union Hospital; Ningbo Medical Center Lihuili Hospital; Shanghai First Maternity and Infant Hospital; Shanghai 6th People's Hospital; Affiliated Hospital of Nantong University
- First posted
- Jan 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Conditions
- Breast Cancer
- Metastatic Cancer
Interventions
SHR-1316Drug
PD-L1 antibody
SHR6390Drug
CDK4/6 inhibitor
Nab paclitaxelDrug
Albumin bound paclitaxel
SERDDrug
Fulvestrant
AIDrug
aromatase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai cancer center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.